Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake

Pelosi E, Messa C, Sironi S et al (2004) Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 31: 932–939

Erasmus JJ, McAdams HP, Patz EFJr et al (1998) Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 170:1369–1373

Higashi K, Ueda Y, Seki H et al (1998) Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39:1016–1020

Jana S, Blaufox MD (2006) Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 36:51–72

Talbot JN, Gutman F, Fartoux L et al (2006) PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 33:1285–1289

Lindholm P, Minn H, Leskinen-Kallio S et al (1993) Influence of the blood glucose concentration on FDG uptake in cancer-a PET study. J Nucl Med 34:1–6

Bettinardi V, Danna M, Savi A et al (2004) Performance evaluation of the new whole-body PET/CT scanner: Discovery ST. Eur J Nucl Med Mol Imaging 31:867–881

Surti S, Karp JS (2004) Imaging characteristics of a 3-dimensional GSO whole-body PET camera. J Nucl Med 45:1040–1049

Brambilla M, Secco C, Dominietto M et al (2005) Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based wholebody PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med 46:2083–2091

Cook GJ, Fogelman I, Maisey MN (1996) Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 26:308–314

Boucher L, Rodrigue S, Lecomte R, Benard F (2004) Respiratory gating for 3-dimensional PET of the thorax: feasibility and initial results. J Nucl Med 45:214–219

Ruers TJ, Langenhoff BS, Neeleman N et al (2002) Value of positron emission tomography with [18F] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 20:388–395

Nehmeh SA, Erdi YE, Pan T et al (2004) Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 31:3179–3186

Slosman DO, Quinodoz M, Willi JP (2005) Breath-hold PET/CT imaging: clinical value in thoracic and upper abdominal investigations. Eur J Nucl Med Mol Imaging 32(Suppl 1):S80

Kubota K, Itoh M, Ozaki K et al (2001) Advantage of delayed whole-body FDG-PET imaging for tumor detection. Eur J Nucl Med 28:696–703

Lowe VJ, DeLong DM, Hoffman JM, Coleman RE (1995) Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 36:883–887

Fischman AJ, Alpert NM (1993) FDGPET in oncology: there’s more to it than looking at pictures. J Nucl Med 34:6–11

Hustinx R, Smith RJ, Benard F et al (1999) Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26:1345–1348

Matthies A, Hickeson M, Cuchiara A, Alavi A (2002) Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871–875

Koyama K, Okamura T, Kawabe J et al (2002) The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 16:169–176

Higashi T, Saga T, Nakamoto Y et al (2003) Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET): usefulness and limitations in “clinical reality”. Ann Nucl Med 17:261–279

Torizuka T, Tamaki N, Inokuma T et al (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36:1811–1817

Nishiyama Y, Yamamoto Y, Monden T et al (2005) Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Comm 26:895–901

Gallagher BM, Fowler JS, Gutterson NI et al (1978) Metabolic trapping as a principle of radiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19:1154–1161

Okazumi S, Isono K, Enomoto K et al (1992) Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 33:333–339